Catalyst
Slingshot members are tracking this event:
FDA set for Q3 2017 action date on AstraZeneca (AZN)'s Lynparza, or olaparib, for relapsed ovarian cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AZN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 17, 2017
Occurred Source:
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2017/lynparza-receives-additional-and-broad-approval-in-the-us-for-ovarian-cancer-17082017.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Relapsed Ovarian Cancer, Olaparib, Lynparza, Fda
